SANTA ANA, CA--(Marketwired - Aug 14, 2013) - BioLargo, Inc. (
"Deodorall Sport is a great example of how we leverage our core technology to create great products and take advantage of a niche marketplace when we find the right strategic partners as we have done here," said BioLargo's president, Dennis Calvert. "We are on the lookout for partners like these in other markets in which our technology has application to continue expanding our sales efforts."
"Any sport that struggles with sweaty gear needs Deodorall Sport," commented Scott Jahnke, President of Proguard. "Our early testing with hockey moms really showed us the market opportunity for total odor elimination for stinky gear, and we are glad to be part of the team as we develop the market together."
About BioLargo, Inc.
We make life better by delivering technology-based products that help solve some of the world's most important problems that threaten our water, food, agriculture, healthcare and energy. Our website is www.BioLargo.com. Our subsidiary Odor-No-More Inc., features award-winning products serving the pet, equine, and consumer markets, including the Nature's Best Solution® and Deodorall® brands. (www.OdorNoMore.com). Our subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in early 2014. Our subsidiary BioLargo Water, Inc. (www.BioLargoWater.com), showcases our "advanced oxidation systems," including its AOS filter, a product in development specifically designed to eliminate common, troublesome, and dangerous (toxic) contaminates in water in a fraction of the time of current technologies. BioLargo also owns a 50% interest in the Isan System, which was honored with a "Top 50 Water Company for the 21st Century" award by the Artemis Project.
Safe Harbor Statement
The statements contained herein, which are not historical, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, the risks and uncertainties included in BioLargo's current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo's Annual Report on Form 10-K for the year ended December 31, 2012.